Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
- 141 Downloads
Volasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve survival with a clinically manageable safety profile, administered alone and in combination with cytarabine in patients with acute myeloid leukaemia.
The objectives of this analysis were to describe the pharmacokinetics of volasertib and cytarabine, administered as single agents or in combination.
Three thousand, six hundred and six plasma volasertib concentrations from 501 patients receiving either volasertib alone, or in combination with cytarabine, and 826 plasma cytarabine concentrations from 650 patients receiving cytarabine as multiple subcutaneous injections per cycle either alone, or in combination with volasertib, were analysed using NONMEM Version 7.3. Covariates evaluated included demographic and disease-related parameters.
The pharmacokinetics of volasertib were found to be dose independent from 150 to 550 mg. Body surface area and ethnicity showed significant effects in all the patients. This is reflected as an increase in drug exposure for Japanese patients, although this finding has to be interpreted with caution because only 7% of patients were part of that population group. Volasertib showed low-to-mild inter-individual variability in total clearance. For the case of cytarabine, its pharmacokinetics was affected by body surface area. Finally, volasertib and cytarabine did not influence the pharmacokinetic characteristics of each other.
The pharmacokinetics of volasertib in patients with acute myeloid leukaemia alone or in combination with cytarabine is predictable and associated with low-to-mild patient variability with the exception of the high variability associated with the volume of distribution of the central compartment, having no effect on the area under the plasma concentration–time curve.
Compliance with Ethical Standards
This work has been funded by Boehringer Ingelheim GmbH & Co.KG.
Conflict of interest
Belén P. Solans and Iñaki F. Trocóniz have received research funding from Boehringer Ingelheim GmbH & Co.KG. Angèle Fleury, Matthias Freiwald, Holger Fritsch an Karin Haug are employed by Boehringer Ingelheim GmbH & Co.KG.
- 3.Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD, USA. http://seer.cancer.gov/csr/1975_2012/. Accessed 2 June 2017.
- 17.Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user’s guides (1989–2015). Ellicott City: Icon Development Solutions; 2015.Google Scholar
- 19.Ahn J, Karlsson M, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. 2008;35(4):401–21.Google Scholar
- 23.Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. 2011;13(2):143–51.Google Scholar
- 24.Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, et al. Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the plk-1 inhibitor BI 2536 and its application in clinical development. Curr Microbiol. 2010;61(4):785–95.Google Scholar